Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four–Month, Phase III Study

Arthritis and Rheumatology

Volumn 71, Issue 6, 2019, Pages 878-891

  van der Heijde, Désirée ^a   Strand, Vibeke ^b   Tanaka, Yoshiya ^c,m   Keystone, Edward ^d,m   Kremer, Joel ^e   Zerbini, Cristiano A F ^f   Cardiel, Mario H ^g   Cohen, Stanley ^h   Nash, Peter ⁱ   Song, Yeong Wook ^j   Tegzová, Dana ^k   Gruben, David ^l   Wallenstein, Gene ^l   Connell, Carol A ^l   Fleischmann, Roy ^h   Hall, Stephen ^m   Nicholls, David ^m   Rischmueller, Maureen ^m   Baker, Milton F ^m   Bessette, Louis ^m   Cividino, Alfred A ^m   Haraoui, Boulos ^m   Niall Jones, Henry ^m   Khraishi, Majed ^m   Thorne, J ^m   Birbara, Charles Allen ^m   Baraf, Herbert Stuart Block ^m   Bathon, Joan Marie ^m   Brodsky, Alan Lawrence ^m   Cush, John Joseph ^m   Dikranian, Ara Hagop ^m   Diri, Erdal ^m   Dura, Paul Andrew ^m   Lohr, Kristine Marie ^m   Fleischmann, Roy Mitchell ^m   Griffin, Robert Michael ^m   Halter, Dale George ^m   Hargrove, Jody Kay ^m   Bouda, David William ^m   Reddy Pasya, Suresh Kumar ^m   Hill, Geneva Louise ^m   Jackson, Raymond Edward ^m   Kafka, Shelly Pearl ^m   Kaine, Jeffrey Louis ^m   Katzenstein, Paul L ^m   Kempf, Kevin James ^m   Kolba, Karen Sue ^m   Kremer, Joel Marc ^m   Longley, Selden ^m   Mathews, Steven D ^m   Milton, Ami Charise ^m   Misischia, Richard James ^m   Moorman, Haydon Anthony ^m   Moreland, Larry Wayne ^m   Niemer, Mark William ^m   Palmer, William Rodney ^m   Sayers, Michael Eugene ^m   Schuette, Patrick Thomas ^m   Shamim, Talha ^m   Shergy, William Julius ^m   Sikes, David Hilton ^m   Silverfield, Joel Charles ^m   Siva, Chokkalingam ^m   Taborn, James D ^m   Walsh, Bridget Tyrell ^m   Wells, Alvin Francis ^m   Wolfe, Sanford Mayer ^m   Adhikari, Prabha ^m   Amano, Kouichi ^m   Bae, Sang Cheol ^m   Chandrashekara, Srikantiah ^m   Chopra, Arvind K ^m   Hsu, Ping Ning ^m   Iwahashi, Mitsuhiro ^m   Kadel, Jugal Kishore ^m   Kawabe, Yojiro ^m   Koh, Eun Mi ^m   Lan, Joung liang ^m   Lee, Soo Kon ^m   Lin, Hsiao Yi ^m   Liou, Lieh bang ^m   Liu, Ming Fei ^m   Migita, Kiyoshi ^m   Miyamoto, Toshiaki ^m   Miyasaka, Nobuyuki ^m   Mori, Shunsuke ^m   Munakata, Yasuhiko ^m   Ohta, Shuji ^m   Park, Won ^m   Park, Sung Hwan ^m   Rao, Uppuluri Ramakrishna ^m   Shim, Seung Cheol ^m   Shobha, Vineeta ^m   Takasaki, Yoshinari ^m   Takeuchi, Tsutomu ^m   Tohma, Shigeto ^m   Tsai, Wen Chan ^m   Ueki, Yukitaka ^m   Veeravalli, Sarath Chandra Mouli ^m   Wagh, Shrikant ^m   Yamanaka, Hisashi ^m   Yoo, Bin ^m   Batalov, Anastas ^m   Bichoversuska, Daniela ^m   Dvorak, Zdenek ^m   Goranov, Ivan ^m   Hrytsenko, Halyna M ^m   Kopackova, Jana ^m   Mosterova, Zdenka ^m   Oparanov, Boycho ^m   Petrov, Andriy ^m   Pokrzywnicka Gajek, Ines ^m   Povoroznyuk, Vladyslav V ^m   Rosa, Jan ^m   Ruzga, Zofia ^m   Settas, Loukas ^m   Stanislavchuk, Mykola A ^m   Tseluyko, Vira Iosypivna ^m   Vitek, Petr ^m   de Freitas Zerbini, Cristiano Augusto ^m   Brenol, Joao Carlos Tavares ^m   Cardiel Rios, Mario H ^m   Escalante, William Jose Otero ^m   Maldonado Lopez, Maria Concepcion ^m   Jaller Raad, Juan Jose ^m   Hernandez, Javier Dario Marquez ^m   Jauregui, Edwin Antonio ^m   Keiserman, Mauro W ^m   Melazzi, Ana Claudia Cauceglia ^m   Pascual Ramos, Virginia ^m   Pinto, Luciana Teixeira ^m   Radominski, Sebastiao C ^m   Ximenes, Antonio Carlos ^m   de Morales, Sol Villegas ^m   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Biopharmaceutical Consultant   (United States)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d MOUNT SINAI HOSPITAL   (Canada)

^e ALBANY MEDICAL COLLEGE   (United States)

^f Centro Paulista de Investigacao Clinica   (Brazil)

^g Centro de Investigacion Clinica de Morelia   (Mexico)

^h METROPLEX CLINICAL RESEARCH CENTER   (United States)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j Seoul National University Hospital   (South Korea)

^k INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^l PFIZER INC   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; METHOTREXATE; PLACEBO; TOFACITINIB; ANTIRHEUMATIC AGENT; JANUS KINASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADENOCARCINOMA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSESSMENT OF HUMANS; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; BOOLEAN REMISSION; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DAS28; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEART ARREST; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; HYPERTENSION; INTERVERTEBRAL DISK HERNIA; JOINT RADIOGRAPHY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; NEUTROPENIA; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY DISTRESS SYNDROME; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SIMPLIFIED DISEASE ACTIVITY INDEX; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS PNEUMONIA; ADULT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JANUS KINASE INHIBITORS; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 85065022988     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40803     Document Type: Article

References (22)

1. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377–86.
2. Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E. Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. RMD Open 2016;2:e000232.
3. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised Phase 3 trial. Lancet 2013;381:451–60.
4. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253–61.
5. Van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four–month phase III randomized radiographic study. Arthritis Rheum 2013;65:559–70.
6. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495–507.
7. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508–19.
8. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837–52.
9. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 2016;18:34.
10. Wollenhaupt J, Silverfield J, Lee EB, Terry K, Kwok K, Strengholt S, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years [abstract]. Arthritis Rheumatol 2017;69 Suppl 10. URL: https://acrabstracts.org/abstract/tofacitinib-an-oral-janus-kinase-inhibitor-in-the-treatment-of-rheumatoid-arthritis-safety-and-efficacy-in-open-label-long-term-extension-studies-over-9-years/.
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
12. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
13. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573–86.
14. National Heart, Lung, and Blood Institute: National Institutes of Health. JNC 7 complete report: the science behind the new guidelines. 2014. URL: https://www.nhlbi.nih.gov/health-pro/guidelines/current/hypertension-jnc-7/complete-report.
15. Canhao H, Rodrigues AM, Gregorio MJ, Dias SS, Melo Gomes JA, Santos MJ, et al. Common evaluations of disease activity in rheumatoid arthritis reach discordant classifications across different populations. Front Med (Lausanne) 2018;5:40.
16. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86–94.
17. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253–62.
18. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2675–84.
19. Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1133–8.
20. Xeljanz (tofacitinib) prescribing information. New York (NY): Pfizer; 2017. URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=959.
21. Buch MH, Aletaha D, Emery P, Smolen JS. Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 2011;70:886–90.
22. Landewé R, van der Heijde D. Follow up studies in rheumatoid arthritis. Ann Rheum Dis 2002;61:479–81.